CURE is pleased to announce the appointment of Erin Duffy, PhD and Eleanor Tandler, MBA to its Board of Directors. The appointments of Dr. Duffy and Ms. Tandler expand the CURE Board to 14 directors.
Dr. Duffy is the chief scientific officer of Melinta Therapeutics. Ms. Tandler is the CEO and founder of NovaTract Surgical.
“I’m delighted to welcome these two talented experts to the CURE Board,” said Dr. Susan Froshauer, president and CEO of CURE. “Their perspective will be invaluable as CURE continues to champion Connecticut’s growing presence in the biotech and medical device industries.”